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erythropoietin users versus those who did not receive the 
drug in a CKD population.  Results: We identified 11 studies 
involving 862 unique patients with CKD. Aggregation of 
study results did not show a significant increase in response 
rates among erythropoietin user versus non-user patients 
(pooled odds ratio = 1.431; 95% CI 0.954; 2.146), according to 
a random-effects model. No heterogeneity was found, the p 
value was 0.1 for our test of study heterogeneity ( Q = 14.147). 
Stratified analysis in various subgroups of interest did not 
significantly change these findings.  Conclusions: Our meta-
analysis showed no link between immunological response 
to HBV vaccine and therapy with human recombinant eryth-
ropoietin among individuals on long-term dialysis. We sug-
gest the use of recombinant vaccine towards hepatitis B in 
patients on regular dialysis irrespective of erythropoietin 
treatment. 
 
Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Control of the spread of hepatitis B virus (HBV) in-
fection in dialysis units has been an important goal in 
the management of end-stage renal disease  [1] . On a 
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 Abstract 
 Background: It is known that the immunogenicity of hepa-
titis B virus (HBV) vaccine is lower in uremic patients than 
healthy subjects. Numerous inherited or acquired factors 
have been implicated in this lowered response, and the high 
frequency of recombinant human erythropoietin use among 
patients on maintenance dialysis has been suggested to play 
a pivotal role. However, the impact of therapy with recombi-
nant erythropoietin on the immune response to HBV vaccine 
in patients with chronic kidney disease (CKD) is not appropri-
ately detailed.  Aim: To evaluate the influence of human re-
combinant erythropoietin therapy on the immunological 
 response to HBV vaccine in CKD patients by performing a 
systematic review of the literature with a meta-analysis of 
clinical studies.  Methods: We used the random-effects mod-
el of DerSimonian and Laird with heterogeneity and sensi-
tivity analyses. The end-point of interest was the rate of pa-
tients showing seroprotective anti-hepatitis B titers at com-
pletion of a hepatitis B vaccine schedule among human 
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global basis, hepatitis B is one of the most important in-
fectious diseases all over the world and patients on 
maintenance dialysis remain at an increased risk of ex-
posure to HBV. If infected, patients on maintenance di-
alysis are at considerable risk of becoming chronic car-
riers due to poor cellular and humoral immune respons-
es  [1] . To prevent transmission of HBV in hemodialysis 
(HD) settings, numerous measures have been made in-
cluding the screening of blood for HBV surface antigen 
(HBsAg), the decline in the number of blood transfu-
sions received by  dialysis patients because of recombi-
nant human erythropoietin (rHuEPO) use, and the im-
plementation of universal and specific measures within 
dialysis rooms, as recommended by the Centers of Dis-
ease Control and  Prevention (CDC; Atlanta, Ga., USA) 
 [2] . Hepatitis B vaccination is another factor responsible 
for the decline in HBsAg incidence rates among dialysis 
patients in recent years. However, recent data underline 
that the proportion of patients and staff within dialysis 
units who receive HBV vaccine on a routine basis is still 
low  [3, 4] .
 Patients on maintenance dialysis typically show a sub-
optimal immune response to HBV vaccine compared 
with the non-uremic population (40–50 vs.  1 95%). In ad-
dition, anti-HBs titers in uremic patients are lower and 
decline faster  [1] . The impaired immune response to HBV 
vaccination appears to extend to other vaccination 
schemes  [5] and may help explain the high incidence of 
general infections in the dialysis population. Previous 
clinical studies have implicated a number of factors as 
predictors of seroconversion to HBV vaccine among pa-
tients on long-term HD  [1] , including rHuEPO which has 
been used widely in the treatment of renal anemia for two 
decades. The goal of this study was to investigate the 
available evidence on the relationship between erythro-
poietin use and immunological response to HBV vaccine 
in a long-term dialysis population by performing a sys-
tematic review of the literature with a meta-analysis of 
clinical studies.
 Material and Methods 
 Search Strategy and Data Extraction 
 We performed electronic searches of the National Li-
brary of Medicine’s MEDLINE database, Current Con-
tents, and manual searches of selected speciality journals 
to identify all pertinent literature. It has previously been 
demonstrated that an electronic search alone may not be 
sensitive enough  [6] . Four MEDLINE database engines 
(Ovid, PubMed, Embase and GratefulMed) were used. 
The key words ‘hepatitis B’, ‘vaccine’, ‘erythropoietin’, 
and ‘chronic kidney disease’ (CKD) were used. Reference 
lists from qualitative topic reviews and published clinical 
trials were also searched. Our search was limited to hu-
man studies that involved individuals aged  1 19 years 
published in the English literature. All articles were iden-
tified by a search from January 1990 to November 2010. 
Data extraction was conducted independently by two in-
vestigators (F.F. and V.D.) and consensus was achieved for 
all data. Studies were compared to eliminate duplicate re-
ports for the same patients, which included contact with 
investigators when necessary. Eligibility and exclusion 
criteria were prespecified.
 Inclusion Criteria  
 We included studies evaluating patients with CKD. 
Studies restricted to students, military recruits or other 
cohorts that involved subjects  ! 19 years of age were ex-
cluded. Many studies have identified an effect of eryth-
ropoietin therapy on response rate to hepatitis B vaccine. 
However, only studies that (i) specified either a relative 
risk and a measure of variance for vaccine response 
among CKD patients on rHuEPO therapy, compared 
with those who did not receive rHuEPO, or (ii) presented 
data in a form that could be used to construct a 2  ! 2 
contingency table were considered for final inclusion. 
Both randomized-controlled trials and observational 
studies were considered eligible for inclusion in the anal-
ysis. We included trials using plasma-derived or recom-
binant DNA hepatitis B vaccine. The decision as to inclu-
sion or exclusion of clinical trials was not related to re-
sults. All dose schedules and routes of administration 
were included, as long as they involved primary vaccina-
tion regimens and not booster doses only. Patients who 
underwent a primary vaccination schedule (naive pa-
tients) or those who had failed to respond to a prior vac-
cine schedule (non-responder patients) against hepatitis 
B were enrolled.
 Ineligible Studies 
 Studies were excluded if they reported inadequate data 
on measures of response, or included individuals with 
positive serology for HBsAg, antibodies to HBsAg (anti-
HBs antibody) or human immunodeficiency virus (anti-
HIV). Reports that were only published as abstracts or as 
interim reports were excluded; letters and review articles 
were not considered for this analysis. Studies that in-
volved renal transplant recipients were excluded.
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 End-Points of Interest 
 We compared the seroprotection rate after comple-
tion of HBV vaccination schedule in CKD patients on 
rHuEPO therapy versus those who did not receive this 
drug. Patients vaccinated against HBV are considered 
immune if protective titers of anti-HBs antibody can be 
demonstrated after completion of vaccination. The level 
of antibody production that defines seroprotection was 
10 IU/ml across the studies. These definitions were con-
sistent with standards published in the scientific litera-
ture.
 Statistical Methods 
 In all reports included in this analysis, data from pa-
tients who did not complete the vaccination schedule 
were excluded from the final analysis; thus, analysis was 
made by per-protocol, not by intention-to-treat. A sum-
mary estimate of the odds ratio (OR) for seroresponse 
after vaccination among CKD patients on rHuEPO ther-
apy versus those who did not receive it was generated by 
use of a random-effects approach, as described by DerSi-
monian and Laird  [7] . Cochrane’s  Q test was used for 
quantifying the heterogeneity  [8] ; the  I 2 index, the per-
centage of total variation across studies due to heteroge-
neity rather than chance  [9] , was also used. The Galbraith 
plot was made to assess the heterogeneity and precision 
of single studies  [10] . Pooled ORs were calculated in sub-
groups of clinical studies as sensitivity analyses. The pub-
lication bias assessment, i.e. the number of void or nega-
tive trials necessary to render the meta-analysis mean-
ingless, was made according to the Klein formula  [11] . 
The publication bias was also measured by the test of fun-
nel plot asymmetry. The 5% significance levels were used 
for   risk. Every estimate was given with its 95% confi-
dence Intervals (95% CI).
 Results 
 Literature Review 
 Our electronic and manual searches identified 94 pub-
lications which were selected for full text review. 83 stud-
ies were excluded because they did not fulfill the inclu-
sion criteria. A list of the 94 bibliographic references is 
available from the authors on request. Eleven papers  [12–
22] , representing a total of 862 unique patients, were in-
cluded in our meta-analysis. There was a 100% concor-
dance between reviewers with respect to final inclusion 
and exclusion of studies reviewed based on the predefined 
inclusion and exclusion criteria.
 Patient Characteristics 
 Some salient demographic characteristics of subjects 
enrolled in the included clinical trials are shown in  ta-
ble 1 . The great majority (8 of 11, 73%) of studies were 
from centers in the developed world. There was 1 ran-
domized clinical trial  [17]  and 10 cohort studies, 2 pro-
spective  [16, 19] and 2 retrospective  [20, 21] . The design 
of the study (prospective or retrospective) remained un-
clear in 5 studies  [12, 13, 15, 18, 22] . Khan et al.  [14] col-
lected prospectively data on HD and retrospectively on 
peritoneal dialysis (PD) patients.
 Most (9/11 = 82%) reports concerned patients on main-
tenance dialysis; 2 addressed CKD patients at the pre-dial-
ysis stage  [18, 19] . Patients on PD and HD were included in 
2 (22%) reports  [14, 21] ; 9 concerned patients on mainte-
nance HD only. Overall, 99 (12%) patients were on PD, 234 
(27%) did not yet require maintenance dialysis, and 529 
(61%) were on maintenance HD. All PD patients received 
continuous ambulatory PD. Only naive patients were ad-
dressed in the studies included in our meta-analysis.
 As listed in  table 2 , recombinant HB vaccine was ad-
ministered by intramuscular route in most clinical stud-
ies. The mean age of subject cohorts ranged from 32 to 68 
years ( table 3 ). The gender distribution ranged from 35 to 
87% male.
 Summary Estimates of Outcome 
 Aggregation of study results did not show a significant 
increase in response rates among rHuEPO users versus 
those patients who did not use the drug, the pooled OR 
was 1.431 (95% CI 0.954; 2.146), according to a random-
effects model. No heterogeneity was found, the p value 
was 0.1 for our test of study heterogeneity ( Q = 14.147).  I 2 
Table 1.  Baseline characteristics of studies included in the analysis
Reference
(first author)
Country Patients
n
Publication
year
Sennesael [12] Belgium 37 1991
Lombardi [13] Italy 35 1992
Khan [14] USA 97 1996
Navarro [15] Spain 36 1996
Peces [16] Spain 80 1997
Anandh [17] India 77 2000
Hassan [18] Israel 69 2003
DaRoza [19] Canada 165 2003
Kara [20] Turkey 15 2004
Chow [21] Hong Kong 64 2006
Afsar [22] Turkey 187 2009
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was 36.4 (95% CI 74.7; 0.0). The test of funnel plot asym-
metry was not significant [  = 2.21; 95% CI –0.39; 4.81 
(p = 0.10)].  Figure 1 shows the test for asymmetry of the 
funnel plot related to cases in  figure 2 .
 We made a stratified analysis in order to obtain more 
homogeneous subgroups of studies.  Table 4 shows that 
pooled ORs did not significantly change and no signifi-
cant heterogeneity occurred among various study sub-
groups. The test of funnel plot asymmetry was not sig-
nificant in all study subgroups (data not shown).
 Discussion 
 Several in vivo and in vitro experiments have shown 
specific and varied deficiencies in the immune response 
of patients with CKD, such as decreased immunoglobu-
lin production, diminished interleukin-2 secretion by T 
lymphocytes, and impaired macrophage function  [23, 
24] . Many clinical factors may be responsible for the low-
er seroconversion rate to recombinant hepatitis B vaccine 
in patients with CKD including older age  [25] , nutrition-
Table 2.  Vaccine schedules of studies included in the analysis
Reference
(first author)
Vaccine route Vaccine schedule
months
Vaccine dose
g
Sennesael [12] recombinant, IM 0, 1, 2, and 6 20
Lombardi [13] Pasteur, IM 0, 1, 2, 3, 4, 5, and 6 5
Khan [14] recombinant, IM 0, 1, 2, and 6 40
Navarro [15] recombinant, IM 0, 1, and 6 40
Peces [16] recombinant, IM 0, 1, 2, and 6 40
Anandh [17] recombinant, IM (n = 41)
recombinant, ID (n = 36)
0, 1, 2, 3, 4, 5, and 6*
0, 1, 2, 3, 4, 5, and 6**
20 
Hassan [18] recombinant, IM 0, 1, 3, and 6 40
DaRoza [19] recombinant, IM
plasma-derived, IM
0, 1, and 6
0, 1, 2, and 6
40
Kara [20] recombinant, IM 0, 1, 2, and 6 40
Chow [21] recombinant, IM 0, 1, and 6 20 (n = 14)
40 (n = 26)
80 (n = 24)
Afsar [22] recombinant, IM 0, 1, 2, and 6 40
* Once a week. ** Twice a week.
Table 3.  Baseline characteristics of studies included in the analysis
Reference (first author) Age, years Males, n (%) Time on dialysis, months
Sennesael [12] 60.3810/55.3811* 16 (55)/9 (53)* 31830/30829*
Lombardi [13] 56814/6886* 22 (63) not available
Khan [14] 48.7816/50.1816** 52 (54) 38858/35858**
Navarro [15] not available 22 (61) not available
Peces [16] 58.581.5 36 (45) 61 (7–220)
Anandh [17] 32816/34811* 67 (87) not available
Hassan [18] 59811/61810* 35 (51) not applicable
DaRoza [19] 59.8814.9 106 (64) not applicable
Kara [20] 51812/38814** 9 (60) 35815/24813**
Chow [21] 43812 33 (51) 8.5 (1–33)
Afsar [22] 45.1814/49.188** 66 (35) 99866/80857**
* Values expressed as control and treatment groups. ** Values expressed as converter and non-converter patients.
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al status  [26] , HIV infection  [27] , possession of the major 
histocompatibility complex haplotype HLA-B  [28] , and 
diabetes mellitus  [29] , among others. Controversial evi-
dence exists about the effect of rHuEPO therapy on the 
outcome of the immune response to four doses of recom-
binant HBV vaccine in a CKD population. Recent data 
indicate that rHuEPO have humoral and cellular immu-
nomodulating properties. As an example, rHuEPO in-
creases immunoglobulin production and proliferation of 
human B cells and B-cell lines  [30] . It increases signifi-
cantly CD4 and CD8 cells without changing the CD4/
CD8 ratio, decreases the number of natural killer cells 
and supports the impaired phagocytic activity among pa-
tients on long-term HD  [31] . Finally, rHuEPO supports in 
vitro T-cell mitogenic proliferation in HD patients  [32] . 
According to this evidence, the activity of rHuEPO on the 
immune response to recombinant HBV vaccine in the 
dialysis population through, at least, some of these im-
munomodulating properties has been suggested.
 Sennesael et al.  [12] were the first to observe higher 
antibody titers (HBsAb) after completion of a vaccine 
schedule in dialysis patients on rHuEPO than in those 
who did not receive it. A significant and positive relation-
ship between anti-HBs titers and T4/T8 lymphocyte ratio 
was described. They suggested an influence of rHuEPO 
administration on antibody titers at completion of the 
vaccine schedule by affecting T-cell subsets.
 Our meta-analysis determined that rHuEPO therapy 
has no impact on the immunological response to hepati-
tis B vaccine in a dialysis population. Our results were 
robust as no significant heterogeneity occurred in pri-
mary and stratified analyses. No publication bias was 
found and analysis of various subgroups yielded only 
minimal changes on the effect size.
 Our findings are consistent with data from other 
sources. In their observational study on 105 patients on 
maintenance HD, Eardley et al.  [33] observed no signifi-
cant difference in mean rHuEPO dose between respond-
er and non-responders dialysis patients after a primary 
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 Fig. 1. Test of funnel plot asymmetry (primary analysis).  Fig. 2. Funnel plot (primary analysis). 
Table 4.  Pooled OR of failure to respond to vaccine (rHuEPO users vs. controls) in various subgroups of interest
Random-effects model
OR (95% CI)
Q (p) I2
All studies (n = 11) 1.431 (0.954; 2.146) 14.147 (0.166) 36.4
Patients on dialysis (n = 9) 1.453 (0.924; 2.287) 11.3 (1.0) 38.3
Cohort studies (n = 10) 1.352 (0.873; 2.093) 13.065 (0.1) 38.8
Patients on HD (n = 6) 1.467 (0.765; 2.813) 9.245 (0.1) 56.7
Studies from the Western world (n = 8) 1.484 (0.97; 2.26) 7.206 (0.4) 16.7
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course of vaccine [6,495 vs. 6,171 IU/week (p = 0.66)]. 
Identical results were obtained by Kovacic et al.  [34] . No 
link between seroresponse rate and rHuEPO therapy, as 
assessed by rate of rHuEPO administration between re-
sponder and non-responder patients, was noted after the 
HBV vaccine schedule in another cohort study  [35] . Liu 
et al.  [36] observed an increment of anti-HBs titers be-
tween the initial month and the seventh month, related 
to rHuEPO dosage, in the control group only.
 This meta-analysis is potentially limited in a number 
of ways. First, the number of patients available for our 
analysis was not very large (n = 862). Secondly, we have 
made a meta-analysis of observational studies and it is 
well known that a meta-analysis of randomized clinical 
trials is provided with better accuracy and reliability  [37] . 
Finally, the quality of the studies included in this system-
atic review was not high and there is increasing evidence 
showing that the quality of studies affect outcome esti-
mates  [37] . The minimal changes on the effect size (pooled 
ORs) obtained with stratified analysis, the complete ab-
sence of heterogeneity and publication bias strengthen 
our conclusions.
 Various approaches have been suggested in order to 
improve the response rate to hepatitis B vaccine in dialy-
sis populations including increased vaccine doses  [35] or 
shots, or intradermal vaccine route  [38, 39] . Higher im-
munogenicity has been observed when HBV vaccine has 
been given to CKD patients not yet requiring regular 
 dialysis  [19] . Numerous vaccine adjuvants have been 
 recommended, such as interferon, interleukin-2, levami-
sole, thymopentin, and granulocyte-macrophage colony-
stimulator factor [reviewed in  1 ]. The CDC currently rec-
ommend that HD patients receive by intramuscular route 
double doses (20   g twice) at 0, 1, and 6 months  [2] . The 
CDC suggest the deltoid as the preferred injection site. 
Adverse reactions are mild and largely confined at the site 
of injection; systemic reactions are uncommon. Regular 
monitoring of antibody levels to ensure that antibody 
concentrations remain above the protective level of 10 
mIU/ml and booster vaccination whenever the levels of 
antibody against hepatitis B surface antigen (anti-HBs ti-
ters) fall below 10 mIU/ml have been recommended  [40] . 
Vaccination with recombinant vaccine should be per-
formed in patients on maintenance dialysis irrespective 
of rHuEPO administration.
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